-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post-Brentuximab and Checkpoint Inhibitor Failure

Program: Education Program
Session: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Biological therapies, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid Malignancies, Adverse Events, young adult , Natural Killer (NK) Cell Therapies, Radiation Therapy, Study Population, Human
Saturday, December 9, 2023, 4:00 PM-5:15 PM

Natalie S. Grover, MD

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

Disclosures: Grover: Tessa Therapeutics: Research Funding; Novartis: Honoraria; Sangamo: Current holder of stock options in a privately-held company; Seattle Genetics: Consultancy; Kite: Honoraria; ADC Therapeutics: Consultancy, Honoraria; Caribou Biosciences: Honoraria; Seagen: Honoraria; Genentech: Honoraria.

OffLabel Disclosure:

<< Previous Presentation | Next Presentation